Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). (abstract)

Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). (abstract). Proc Am Soc Clin Onc. 2005.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.